文献速递肾小球疾病

PLA2R抗体:肾病综合征与膜性肾病中的多面生物标志物

PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

本文系统评价了PLA2R抗体检测在原发性膜性肾病诊断中的价值。ELISA法(cut-off 20 RU/mL)合并敏感度0.64、特异度94.7%;免疫荧光法(阈值1:10)合并敏感度0.69、特异度0.98。在ELISA≥20 RU/mL且充分二次筛查时,可能无需肾活检;但低水平或阴性者仍需活检。

要点

  • PLA2R抗体是原发性膜性肾病一线诊断工具,可识别PLA2R相关MN。
  • ELISA法≥20 RU/mL且充分二次筛查时,可能无需肾活检。
  • ELISA低水平或阴性者仍需肾活检以明确诊断。

核心结论

  • PLA2R抗体检测有助于诊断PLA2R相关膜性肾病,在ELISA≥20 RU/mL且充分二次筛查时可能无需肾活检。

主要发现

  • EUROIMMUN ELISA法(cut-off 20 RU/mL)合并敏感度0.64(95%CI 0.56-0.72),特异度94.7%(95%CI 90.5-97.1%)。
  • EUROIMMUN免疫荧光法(阈值1:10)合并敏感度0.69(95%CI 0.637-0.739),特异度0.98(95%CI 0.931-0.994)。
  • 免疫荧光法研究的偏倚风险高于ELISA法。
  • 指标检测时机对合并诊断准确性结果无显著影响。

关键数值与推荐

  • ELISA法cut-off值为20 RU/mL,免疫荧光法阈值为1:10。
  • 采用QUADAS-2工具评估偏倚风险。

临床怎么用

  • PLA2R抗体检测可作为原发性膜性肾病一线诊断工具,减少对肾活检的依赖。
  • ELISA≥20 RU/mL且充分二次筛查时,可考虑不进行肾活检;低水平或阴性者仍需活检。

局限性

  • 免疫荧光法研究的偏倚风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phospholipase A2 receptor antibody (PLA2R-Ab) test is a valuable first-line diagnostic tool for primary membranous nephropathy (MN), helping to identify PLA2R-related MN and potentially eliminating the need for a kidney biopsy in some individuals. By reducing the reliance on biopsies, the test streamlines diagnosis and improves patient care. However, determining the optimal PLA2R measurement method and cut-off is critical to maximizing the benefits of the test and minimizing any harms. A systematic review and meta-analysis were performed to evaluate serum- and urine-based biomarkers for distinguishing between PLA2R-related MN and non-PLA2R MN. Searches were conducted in databases including Medline, Embase, Cochrane Library, Scopus, Web of Science, International HTA Database and ClinicalTrials.gov. The methodology followed Cochrane-recommended guidelines for systematic reviews and meta-analyses, and the QUADAS-2 tool was utilized to assess the overall risk of bias. Ninety-one studies met the eligibility criteria for inclusion in the review. Of these, 38 studies reporting the accuracy of the PLA2R-Ab test using the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) method and 27 using the EUROIMMUN immunofluorescence (IF) method were suitable for meta-analysis. The pooled sensitivity and specificity of EUROIMMUN ELISA at a cut-off value of 20 RU/mL were 0.64 [95% confidence interval (CI) 0.56-0.72] and 94.7% (95% CI 90.5-97.1%), respectively. The pooled sensitivity and specificity of EUROIMMUN IF at a threshold of 1:10 was 0.69 (95% CI 0.637-0.739) and 0.98 (95% CI 0.931-0.994), respectively. Risk of bias was higher for studies evaluating the IF compared with ELISA test. We also explored whether the timing of the index test had an impact on the pooled diagnostic accuracy results; no significant differences were found. By evaluating the specificity and sensitivity of EUROIMMUN ELISA PLA2R-Ab and IF, we demonstrate that at ELISA levels ≥20 RU/mL, alongside thorough secondary screening, a kidney biopsy may be unnecessary. However, lower or negative levels still warrant a biopsy.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ragy O, Abass W, Kanigicherla DAK, et al. PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrol Dial Transplant. 2025. PMID: 39820570. doi:10.1093/ndt/gfaf012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。